Neurocrine Biosciences Inc (NBIX NASDAQ) stock market data APIs
$141.6064
-0.27(-0.2%)
as of September 17, 2025
Try our APIs with
free plan!
Neurocrine Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Prev. Close
141.6064
Open
141.3359
High
142.8735
Low
140.8289
52 wk Range
84.23-154.61
Market Cap
14 156 M
P/E Ratio
42.2278
Shares Outstanding
99 182 K
Revenue
2 510 M
EPS
1.06
Beta
0.283
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurocrine Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurocrine Biosciences Inc data using free add-ons & libraries
Get Neurocrine Biosciences Inc Fundamental Data
Neurocrine Biosciences Inc Fundamental data includes:
- Net Revenue: 2 510 M
- EBITDA: 528 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-30
- EPS/Forecast: 0.99
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurocrine Biosciences Inc News
New
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO, Sept. 16, 2025 /PRN...
What Does Wall Street Think About Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX)...
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutio...
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation
Investors seeking growth opportunities without overpaying often turn to the Growth At Reasonable Price (GARP) strategy, which targets companies demonstrating strong expansion metrics alongside reasona...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
